We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Manufacturing Issues Are Cause Of Impax NDA Rejection
Manufacturing Issues Are Cause Of Impax NDA Rejection
January 25, 2013
The FDA’s rejection of Impax Pharmaceuticals’ extended-release capsule Rytary for the treatment of idiopathic Parkinson’s disease points to continuing problems at a California manufacturing site.